Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pancreas

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    511 result(s) found for: Pancreas. Displaying page 1 of 26.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-006260-29 Sponsor Protocol Number: CIOCC 012007 Start Date*: 2008-02-22
    Sponsor Name:Fundación Hospital de Madrid
    Full Title: "Estudio farmacodinámico Fase "0" de Micofenolato Mofetil (MMF, CellCept) en pacientes con cáncer de pancreas"
    Medical condition: Cáncer de Pancreas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014407-31 Sponsor Protocol Number: 09.07 Start Date*: 2009-10-06
    Sponsor Name:Odense Universitetshospital
    Full Title: Randomiseret fase II forsøg med irinotecan, cetuximab og everolimus (ICE) sammenlignet med capecitabin og oxaliplatin (CapOx) til patienter med gemcitabin resistent pancreascancer.
    Medical condition: Patienter med gemcitabin resistent pancreascancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000178-21 Sponsor Protocol Number: 0000767 Start Date*: Information not available in EudraCT
    Sponsor Name:Altus Pharmaceuticals Inc.
    Full Title: An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
    Medical condition: Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011765 Cystic fibrosis pancreas LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) IT (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017716-32 Sponsor Protocol Number: MEC09/02 Start Date*: 2010-12-30
    Sponsor Name:Academic Medical Center
    Full Title: A phase II, randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib and metformin in patients with locally advanced and metastastatic pancreatic c...
    Medical condition: locally advanced and metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    llt 10033604 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004623-17 Sponsor Protocol Number: 26092020 Start Date*: 2021-11-09
    Sponsor Name:Zealand University Hospital
    Full Title: Irreversible electroporation in combination with immune checkpoint inhibi-tion , in patients with metastatic pancreatic cancer - A prospective, phase 2 study
    Medical condition: Patients with non-curable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004491-22 Sponsor Protocol Number: LIFE-PC-01 Start Date*: 2017-09-01
    Sponsor Name:Dept. Clinical Medicine, Aarhus Universit
    Full Title: Early detection of effects of chemotherapy in pancreatic cancer patients – a study using MR-hyperpolarization scanning based on hyperpolarized Pyruvate (13C) injection
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019588-12 Sponsor Protocol Number: Bay86-9766/14905 Start Date*: 2010-08-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multi-center, phase I/II study of BAY 86-9766 in combination with gemcitabine in patients with locally advanced inoperable or metastatic pancreatic cancer
    Medical condition: Pancreatic cancer is the eighth most common cause of cancer-related death worldwide, associated with a 5-year survival rate of 5-6%. A vast majority of patients present with incurable advanced dise...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    16.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    16.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003855-11 Sponsor Protocol Number: 025/05 Start Date*: Information not available in EudraCT
    Sponsor Name:Klinikum Großhadern, University of Munich / Medical Director: Prof. Dr. med. Burkhard Götze
    Full Title: Gemcitabine and cisplatin in combination with hyperthermia in patients with locally advanced or metastatic pancreatic cancer as second-line therapy after adjuvant or first-line chemotherapy with Ge...
    Medical condition: Combination of standard chemotherapy with Gemcitabine and Cisplatin and regional hyperthermia in patients with locally advanced or metastatic pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2008-002791-10 Sponsor Protocol Number: HE 3/07 Start Date*: 2009-01-21
    Sponsor Name:Hellenic Cooperative Oncology Group (HeCOG)
    Full Title: GEMCITABINE COMBINED WITH THE mTOR INHIBITOR TEMSIROLIMUS (CCI-779) IN PATIENTS WITH INOPERABLE OR METASTATIC PANCREATIC CANCER
    Medical condition: advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003594-41 Sponsor Protocol Number: CSOM230c2401 Start Date*: 2008-11-26
    Sponsor Name:Uppsala University Hospital, Dept of Medical Scienses
    Full Title: An open label, multi-centre study of pasireotide LAR in addition to chemotherapy in patients with non-functioning, endocrine pancreatic tumors
    Medical condition: Non-functioning endocrine pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003528-19 Sponsor Protocol Number: Start Date*: 2013-04-16
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial
    Full Title: STEM CELL TRANSPLANTATION FOR ERADICATION OF MINIMAL PANCREATIC CANCER PERSISTING AFTER SURGICAL EXCISION
    Medical condition: pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-009928-37 Sponsor Protocol Number: CONKO-008 Start Date*: 2009-10-21
    Sponsor Name:Charite Universitätsmedizin Berlin
    Full Title: Phase 1/2 Studie: CONKO-008 Oxaliplatin/Folinsäure/5-Fluorouracil (24h) in Kombination mit Lapatinib in der Zweitlinientherapie des Pankreaskarzinoms nach Progress unter Gemcitabin-Monotherapie
    Medical condition: Pancreatic cancer patients who failed first line therapy with gemcitabine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004097-28 Sponsor Protocol Number: BRD/06/078 Start Date*: 2007-01-12
    Sponsor Name:University College Hospitals NHS Foundation Trust/ University College London
    Full Title: A Phase 1 Trial of Verteporfin Photodynamic Therapy in Unresectable Pancreatic Carcinoma (VERTPAC-01 study)
    Medical condition: Unresectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001219-11 Sponsor Protocol Number: PNCRLPCYS3001 Start Date*: 2015-03-31
    Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
    Full Title: A randomized double-blind (withdrawal) phase 3 study to evaluate the efficacy and tolerability of pancrelipase MT capsules compared with placebo in the treatment of subjects with cystic fibrosis-d...
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10011765 Cystic fibrosis pancreas LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000294-39 Sponsor Protocol Number: INCB18424-363 Start Date*: 2014-07-16
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who ...
    Medical condition: Advanced or metastatic adenocarcinoma of the pancreas in patients that have failed or are intolerant to first-line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10033607 Pancreatic cancer recurrent LLT
    17.1 100000004864 10033606 Pancreatic cancer non-resectable LLT
    17.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    17.1 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Prematurely Ended) DK (Completed) PT (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-005147-17 Sponsor Protocol Number: AIO-PAK-0216 Start Date*: 2018-01-30
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Second-line therapy with Nal-IRI/5-FU/FA after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy
    Medical condition: locally advanced or metastatic pancreatic cancer after failure of a gemcitabine/nab-paclitaxel 1st-line treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    21.0 100000004864 10033607 Pancreatic cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003086-14 Sponsor Protocol Number: EFC6596 Start Date*: 2006-10-09
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A Randomized, Open Label Multi-Center Study of Single Agent Larotaxel (XRP9881) Compared to Continuous Administration of 5-FU For The Treatment of Patients With Advanced Pancreatic Cancer Previousl...
    Medical condition: Advanced Pancreatic Cancer.
    Disease: Version SOC Term Classification Code Term Level
    11.1 10033604 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) DE (Completed) IT (Completed) GB (Completed) HU (Completed) FI (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-002586-36 Sponsor Protocol Number: PACT-9 Start Date*: 2005-07-01
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: PEXG VERSUS PDXG IN LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA : RANDOMIZED, PHASE II STUDY.
    Medical condition: PANCREAS TUMOR TREATMENT
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033609 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021477-36 Sponsor Protocol Number: NEOPAC Start Date*: 2015-01-30
    Sponsor Name:Gesellschaft für Studienmanagement und Onkologie mbH
    Full Title: Adjuvant chemotherapy versus NEOadjuvant gemcitabine/ oxaliplatin plus adjuvant gemcitabine in resectable PAncreatic Cancer: a randomized multicenter phase III study
    Medical condition: resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10033608 Pancreatic cancer resectable LLT
    17.1 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000703-40 Sponsor Protocol Number: KFE10.08 Start Date*: 2011-06-24
    Sponsor Name:Odense University Hospital
    Full Title: Clinical trial with chemotherapy for patients with non-resectable, locally advanced pancreatic cancer and addition of chemo-radiotherapy for patients with borderline resectable pancreatic cancer. ...
    Medical condition: Patients with non-resectable or resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033608 Pancreatic cancer resectable LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:50:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA